1300022I university of maryland, baltiomore; vteu; to 16-0024.B1C1D1.0067--22 base task order funding; biod can 8470038; $2,862,677
Ended Awarded Last action
- Contract number
- HHSN27200022
- Awardee
-
University Of Maryland, Baltimore UEI Z9CRZKD42ZT1 Part of University System Of Maryland
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,067,851
Award facts
- Opportunity
-
- NIAIDDMIDNIHAI2012144 Solicitation number
- Vaccine and treatment evaluation units (vteu) Award Notice · Posted Mar 29, 2012
- Contract value 100% obligated
- $5,067,850.63 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Baltimore, MD 21201, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$109,593 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | -$0 | |
| Funding Only Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $2,314,767 | |
| Original award | $2,862,677 |
About this award
This is a federal contract award from the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases to the University of Maryland, Baltimore, a state-affiliated educational institution, for up to $5,067,850.63 to support the Vaccine and Treatment Evaluation Units (VTEU) program. The contract, a Delivery Order, has a completion date of March 31, 2023 and provides $2,862,677 in base funding for task order work. The contract supports biomedical research and public health initiatives, including a series of Phase II clinical studies to assess the safety and immunogenicity of a H7N9 influenza vaccine administered with the seasonal flu vaccine. The University of Maryland, Baltimore has subcontracted portions of this work to the Centre Pour LE Developpement DES Vaccins-Mali. This contract has no set-aside designation.
Quick answers
Who was awarded contract HHSN27200022?
HHSN27200022 was awarded to University Of Maryland, Baltimore by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 11, 2017.
How much is contract HHSN27200022 worth?
The government has obligated $5,067,851 on HHSN27200022.
Is contract HHSN27200022 an order under another contract?
Yes. HHSN27200022 is a delivery order under HHSN272201300022I, an indefinite delivery contract, on Vaccine and Treatment Evaluation Units (VTEU).
Was contract HHSN27200022 competed?
The extent of competition for HHSN27200022 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award